Therapeutics News and Research

RSS

Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-5902 during a poster session at the American Association for Cancer Research 102nd Annual Meeting being held in Orlando, Florida, April 2-6, 2011, at the Orange County Convention Center.

31 Mar 2011

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced that it has obtained exclusive rights from New York University for intellectual property covering methods of use in modulating microRNA-33a and microRNA-33b for metabolic diseases such as atherosclerosis and metabolic syndrome.

31 Mar 2011

EntreMed fourth quarter revenue is $3.7 million for fiscal year 2010

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three months and twelve months ended December 31, 2010.

30 Mar 2011

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

Silence Therapeutics plc a leading global RNA interference therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, have been accepted for poster presentation at the 2011 American Society of Clinical Oncology Annual Meeting.

30 Mar 2011

Orthopedic surgeons prefer Genzyme's 3-cycle hyaluronic-acid in the U.S., Europe

According to a comprehensive global survey of orthopedic surgeons conducted by iData Research, the leading authority in medical device and pharmaceutical market research, orthopedic surgeons prefer 3-cycle hyaluronic-acid viscosupplementation treatment in the U.S., Europe and Latin Ameica, but are willing to try single-injection products such as Synvisc-One from Genzyme and MONOVISC from Anika Therapeutics.

30 Mar 2011

Positive results from Vertex VX-770 Phase 3 trial against CF

Vertex Pharmaceuticals Incorporated today announced positive results from a 24-week analysis of the ongoing Phase 3 ENVISION study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

30 Mar 2011

Researchers develop new drug for multiple cancer treatment

Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug called AT-406 with potential to treat multiple types of cancer.

30 Mar 2011

EC grants marketing authorization for GSK, Valeant's Trobalt to treat epilepsy

GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced today that the European Commission has granted marketing authorisation for Trobalt as an adjunctive treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.

30 Mar 2011

Osseon launches Osseoflex BT Steerable Bone Tamp for physicians

Osseon Therapeutics announced today at the Society of Interventional Radiology's Annual Meeting the launch of the Osseoflex BT Steerable Bone Tamp.

30 Mar 2011

SRI International, CDD receive NIAID grant to develop TB information repository

SRI International, an independent nonprofit research and development organization, and Collaborative Drug Discovery, provider of a web-based drug discovery software platform, announced that they have been awarded a grant to support the first year of a software development project focused on tuberculosis drug discovery efforts.

29 Mar 2011

PPD introduces new mobile application for clinical trial searches

PPD, Inc. today announced it has launched its new Clinical Trials Mobile application for use on Apple iPad and Apple iPhone devices to help potential clinical research participants and investigators find clinical trials across a wide range of therapeutic areas.

29 Mar 2011

Nycomed submits teduglutide MAA to EMA for SBS treatment

NPS Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported that Nycomed, a global pharmaceutical company, headquartered in Switzerland, has submitted a Marketing Authorization Application to the European Medicines Agency for clearance to market teduglutide as a once-daily subcutaneous treatment for short bowel syndrome.

29 Mar 2011

CPRIT awards $36.7 million grant to UT Southwestern for cancer research

The Cancer Prevention and Research Institute of Texas has awarded more than $36.7 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer investigators.

29 Mar 2011

ADDF awards Yuma $249,810 grant for Alzheimer's research

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $249,810 to Yuma Therapeutics Corporation to develop small molecules to treat Alzheimer's disease.

28 Mar 2011

A.P. Pharma fourth quarter revenue decreases to $1.6 million

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its fourth quarter and full year ended December 31, 2010 and provided a corporate update.

28 Mar 2011

MRF: FDA's decision on Yervoy offers new treatment options for patients with melanoma

Thirteen years of waiting is now over for melanoma patients. That's how long it's been since the last therapy became available to treat the most lethal form of skin cancer – melanoma. The FDA today announced approval of Yervoy, an immunotherapy treatment for advanced melanoma.

28 Mar 2011

Essex scientists receive £205,000 grant for breast cancer research

Scientists from the University of Essex have received a £205,000 grant from Cancer Research UK to investigate the early reversible changes in the genes associated with breast cancer development.

28 Mar 2011

University of Aberdeen, TPP enter agreement to develop novel future medicines

TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.

28 Mar 2011

Molecular pharmacologist receives AACR Award for cancer research

Susan Band Horwitz, Ph.D., will receive the Eighth Annual AACR Award for Lifetime Achievement in Cancer Research. Horwitz conducted pioneering research by discovering the mechanism of action of the chemotherapeutic drug paclitaxel, which prompted the development of this drug as an important therapy for many common solid tumors, including ovarian, breast, and lung carcinomas.

28 Mar 2011

Anergis SA closes funding round for allergy vaccines

Anergis SA announced today that it has closed a Series A financing round raising CHF 18 millions from European biotech funds and private local investors.

28 Mar 2011